Inphi Posts In-Line Results; USANA Disappoints

Inphi (IPHI) is higher in after hours trading after the company posted financial results for Q2, or the quarter ended June 30, 2014, that matched analysts’ expectations, and provided guidance for Q3 in line with forecasts. Shares are up 1.17% at $12.94, with a 52-week range of $10.87 – $16.56.

The provider of high-speed analog semiconductor solutions for the communications and computing markets reported Q2 GAAP net income of $2.6 million, or $0.08 per share, compared with net loss of $1.5 million, or $0.05 loss per share in the prior-year period. Non-GAAP net income was $2.9 million, or $0.09 per share, versus net income of $0.3 million, or $0.01 per share in the same period last year. The Capital IQ analyst estimate is for $0.09 EPS.

Revenue was $33.9 million, up 39% from $24.3 million in the same quarter last year. Analysts were expecting revenue of $33.73 million. The company expects Q3 EPS of $0.10 – $0.12 on revenue of $35.6 million – $37 million. The Street view is EPS of $0.10 on revenue of $35.60 million.

Shares of USANA Health Sciences (USNA) plunged in after-hours as the company reports a lower year-over-year Q2 performance that left results below the consensus of analysts polled by Capital IQ. Full-year guidance is mixed vs. the Street view.

Q2 EPS of $1.36 fell short of analyst estimates of $1.50, and represent a decrease compared to prior-year EPS of $1.72. Revenues of $188.3 million also missed analyst estimates for $201.1 million, and mark a decline compared with revenues of $189.1 million in the prior-year period. USNA reiterated its full-year 2014 guidance for EPS between $5.50-$5.65, shy of analyst estimates for EPS of $5.66; and net sales between $770 million and $790 million, in range of analyst estimates for $784.9 million.

Shares of USNA are down 8.9% at $62.50 after-hours.